Collect Product
Product Details
FAB
- Comprehensive validation - Validated with various antibody subtypes and antibody drugs.
- Simple and fast operation - No complicated washing steps, significantly reducing time.
- High batch consistency - Strict control over raw materials and finished product quality, ensuring a stable supply.
- Accurate and reliable results - High sensitivity with minimal matrix effects.
- High throughput capability - Support multiple product specifications, ideal for high-throughput screening.
- Fast completion - Results in just 1 hour.
Product Specifications
Assay TypeCompetition-TR-FRETReactivityHumanRegulatory StatusRUOAssay Time1 hrSample volume10 μLProduct Overview
The Human Fc gamma RIIA / CD32a (H167) binding Kit (TR-FRET) is based on a homogeneous (no wash) competition TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer) to measure the interaction between human CD32a (H167) and antibody drug candidates or CD32a (H167) inhibitors. It is designed to facilitate the ADCC and ADCP functional performance evaluation of antibody drug candidates, high-throughput screening of CD32a (H167) inhibitors within 0.5-1 hours. It can also be used as a universal detection tool to identify the ability of antibody drugs to bind to human CD32a (H167).
Storage
1. Unopened kit should be stored at 2℃-8℃ upon receiving.
2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
Materials Provided
IDComponentsSizeFRT04-C01Human Fc gamma RIIA / CD32a (H167) Protein Europium-chelate100 tests/500 testsFRT04-C02FA labeled human IgG antibody100 tests/500 testsFRT04-C03Human IgG Standard400 μg/100 tests 2 mg/500 testsDB-04TR-FRET Sample Dilution Buffer, pH7.450 mL/100 tests & 500 testsDB-05TR-FRET Detection Buffer, pH7.450 mL/100 tests & 500 testsAssay Principles
This Human Fc gamma RIIA / CD32a (H167) binding Kit (TR-FRET) is based on TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer). This assay uses the mixture of biotinylated human Fc gamma RIIA / CD32a (H167) and Europium-chelate labeled streptavidin as the Donor and FA labeled human IgG antibody as the Acceptor.
ACRO Quality Management System
Kunden haben auch angesehen
Data Display
Bioactivity-TR-FRET
Please refer to DS document for the assay protocol.
In this TR-FRET assay, Human Fc gamma RIIA / CD32a (H167) Protein Europium-chelate is used as the Donor and FA labeled human IgG antibody is used as the Acceptor. An inhibition Assay was performed to evaluate the interaction between Human Fc gamma RIIA / CD32a (H167) Protein Europium-chelate and FA labeled human IgG antibody using Human IgG standard resulting in a typical IC50 of 482.3 nM (QC tested).
The kit can be used to detect different subclasses of human IgG (human IgG1, human IgG2, human IgG3 and human IgG4). As shown in the figure, human CD32a (H167) has the strongest affinity for human IgG3, followed by human IgG2 and human IgG1, and binds most weakly to human IgG4.
The kit has been used to detect different subclasses of mouse IgG (mouse IgG1, mouse IgG2a and mouse IgG2b), which exhibit different IC50 results. As shown in the figure, human CD32a (H167) binds to mouse IgG1, mouse IgG2a and mouse IgG2b with a low affinity.
This kit was used to evaluate four FDA-approved antibody drugs with different affinities for human CD32a (H167). Bevacizumab binds to human CD32a (H167) with high affinity, Efgartigimod alfa binds relatively weakly, while Toripalimab and Eculizumab show almost no binding.
User Reviews Publish Comment
Frontier Progress
Drug Development Progress- English Name：
Low affinity immunoglobulin gamma Fc region receptor II-a
- Category：
- Listed Drugs Count：
0 Details
- Clinical Drugs Count：
2 Details
- Highest R&D Stage：
Phase 1 Clinical
Contact Us
Drug Candidate Licensing
